Organización Sanitaria Integrada Debagoiena
Organización de Osakidetza
![Foto de Organización Sanitaria Integrada Debagoiena](/img/noimage.png)
![Foto de Hospital Virgen del Camino](/img/noimage_org.png)
Hospital Virgen del Camino
Pamplona, EspañaPublicaciones en colaboración con investigadores/as de Hospital Virgen del Camino (17)
2022
-
Health-related quality of life in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis treated with certolizumab pegol
Farmacia Hospitalaria, Vol. 46, Núm. 1, pp. 27-30
2021
-
Mediterranean diet and risk of dementia and alzheimer’s disease in the epic-spain dementia cohort study
Nutrients, Vol. 13, Núm. 2, pp. 1-19
2020
-
Incidence of Dementia and Associated Factors in the EPIC-Spain Dementia Cohort
Journal of Alzheimer's Disease, Vol. 78, Núm. 2, pp. 543-555
2019
-
Survival and clinical events related to end-stage liver disease associated with HCV prior to the era of all oral direct-acting antiviral treatments
Expert Review of Gastroenterology and Hepatology, Vol. 13, Núm. 7, pp. 699-708
2018
-
Economic evaluation of a population strategy for the treatment of chronic hepatitis C with direct-acting antivirals
Revista Espanola de Enfermedades Digestivas, Vol. 110, Núm. 10, pp. 621-628
2017
-
Cost-effectiveness analysis of therapeutic options for chronic hepatitis C genotype 3 infected patients
Expert Review of Gastroenterology and Hepatology, Vol. 11, Núm. 1, pp. 85-93
2016
-
Cost-effectiveness analysis of simeprevir with daclatasvir for non-cirrhotic genotype-1b-naïve patients plus chronic hepatitis C
Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 16, Núm. 2, pp. 285-294
-
Cost-effectiveness analysis of sofosbuvir-simeprevir regimens for chronic hepatitis C genotype 1 patients with advanced fibrosis
Medicina Clinica, Vol. 146, Núm. 2, pp. 61-64
-
Sofosbuvir plus simeprevir for the treatment of genotype 1 chronic hepatitis C: a review of evidence
Expert Review of Gastroenterology and Hepatology, Vol. 10, Núm. 11, pp. 1289-1303
2015
-
Cost-effectiveness analysis of sofosbuvir-based regimens for chronic hepatitis C
Gut, Vol. 64, Núm. 8, pp. 1277-1288
2014
-
Cost-effectiveness of protease inhibitor based regimens for chronic hepatitis C: A systematic review of published literature
Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 14, Núm. 3, pp. 387-402
2013
-
Cost-effectiveness analysis of triple therapy with protease inhibitors in treatment-naive hepatitis C patients
PharmacoEconomics, Vol. 31, Núm. 10, pp. 919-931
-
Los costes del ictus en España según su etiología. El protocolo del estudio CONOCES
Neurologia, Vol. 28, Núm. 6, pp. 332-339
2012
-
Adherencia subóptima al tratamiento en la esclerosis múltiple
Farmacia Hospitalaria, Vol. 36, Núm. 3, pp. 124-129
2010
-
Angina de Prinzmetal en paciente tratado con capecitabina: a propsito de un caso
Farmacia Hospitalaria
2009
-
Síndrome mielodisplásico. Papel terapéutico de la azacitidina
Atencion Farmaceutica, Vol. 11, Núm. 3, pp. 151-160
2008
-
Tratamiento de linfoma difuso de células B mediastínico durante el embarazo
Farmacia Hospitalaria